Natera Upgrades Prenatal Test to Improve low Fetal Fraction Accuracy

MT Newswires Live05-26

Natera (NTRA) said Tuesday that it has upgraded its Panorama non-invasive prenatal test using SNP-informed deep sequencing to improve accuracy in samples with low fetal fraction.

The genetic testing company said low fetal fraction has been a limitation in some existing prenatal screening methods.

Fetal fraction is the proportion of placental DNA in a pregnant patient's blood that can affect test reliability, the company said.

In a study of 3,323 patients, Natera said the updated test showed strong detection rates for chromosomal abnormalities and reduced the no-call rate to 0.5%, allowing more patients to get results from a single blood draw.

Shares of the company were up 3% in recent Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment